de Boer Albertus G, Gaillard Pieter J
Blood-Brain-Barrier Research Group, Division of Pharmacology, Leiden-Amsterdam Center for Drug Research, University of Leiden, Leiden, The Netherlands.
Clin Pharmacokinet. 2007;46(7):553-76. doi: 10.2165/00003088-200746070-00002.
The blood-brain barrier (BBB), together with the blood-cerebrospinal-fluid barrier, protects and regulates the homeostasis of the brain. However, these barriers also limit the transport of small-molecule and, particularly, biopharmaceutical drugs such as proteins, genes and interference RNA to the brain, thereby limiting the treatment of many brain diseases. As a result, various drug delivery and targeting strategies are currently being developed to enhance the transport and distribution of drugs into the brain. In this review, we discuss briefly the biology and physiology of the BBB as the most important barrier for drug transport to the brain and, in more detail, the possibilities for delivering large-molecule drugs, particularly genes, by receptor-mediated nonviral drug delivery to the (human) brain. In addition, the systemic and intracellular pharmacokinetics of nonviral gene delivery, together with targeted brain imaging, are reviewed briefly.
血脑屏障(BBB)与血脑脊液屏障共同保护并调节大脑的内环境稳定。然而,这些屏障也限制了小分子药物,尤其是蛋白质、基因和干扰RNA等生物制药药物向大脑的转运,从而限制了许多脑部疾病的治疗。因此,目前正在开发各种药物递送和靶向策略,以增强药物向大脑的转运和分布。在本综述中,我们简要讨论作为药物向大脑转运最重要屏障的血脑屏障的生物学和生理学,并更详细地讨论通过受体介导的非病毒药物递送将大分子药物,特别是基因递送至(人类)大脑的可能性。此外,还简要综述了非病毒基因递送的全身和细胞内药代动力学以及靶向脑成像。